US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% NVDA $233.95 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% JNJ $256.03 ▲+0.00% SPCX $158.96 ▲+0.00%
FinancialContent

Articles published by Cyclo Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH RFL
News headline image
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH RFL
News headline image
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers AMTI CYTH
News headline image
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH RFL
News headline image
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers AMTI CYTH
News headline image
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH RFL
News headline image
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH RFL
News headline image
Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH RFL
News headline image
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH RFL
News headline image
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH RFL
News headline image
Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
News headline image
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Tickers CYTH
< Previous 1 2 Next >